Suppr超能文献

先天性肾上腺皮质增生症中的17α-羟化酶/17,20-裂解酶缺乏症:一例报告。

17α‑hydroxylase/17,20‑lyase deficiency in congenital adrenal hyperplasia: A case report.

作者信息

Xu Simiao, Hu Shuhong, Yu Xuefeng, Zhang Muxun, Yang Yan

机构信息

Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China.

出版信息

Mol Med Rep. 2017 Jan;15(1):339-344. doi: 10.3892/mmr.2016.6029. Epub 2016 Dec 12.

Abstract

Congenital adrenal hyperplasia (CAH) is a rare autosomal recessive disorder caused by mutations in the cytochrome P450 family 17 subfamily A member 1 (CYP17A1) gene located on chromosome 10q24.3, which leads to a deficiency in 17α‑hydroxylase/17,20‑lyase. The disorder is characterized by low blood levels of estrogens, androgens and cortisol, which leads to a compensatory increase in adrenocorticotropic hormone levels that stimulate the production of mineralocorticoid precursors. This subsequently leads to hypertension, hypokalemia, primary amenorrhea and sexual infantilism. Over 90 distinct genetic lesions have been identified in patients with this disorder. The prevalence of common mutation of CYP17A1 gene differs among ethnic groups. Treatment of this disorder involves replacement of glucocorticoids and sex steroids. Estrogen alone is prescribed for patients who are biologically male with 17α‑hydroxylase deficiencies that identify as female. However, genetically female patients may receive estrogen and progesterone supplementation. In the present study, a 17‑year‑old female with 17α‑hydroxylase/17,20‑lyase deficiency that presented with primary amenorrhea and sexual infantilism and no hypertension, was examined. The karyotype of the patient was 46, XX, and genetic analysis revealed the presence of a compound heterozygous mutation in exons 6 and 8, leading to the complete absence of 17α‑hydroxylase/17,20‑lyase activity. The patient was treated with prednisolone and ethinyl estradiol. In addition, a summary of the recent literature regarding CAH is presented.

摘要

先天性肾上腺皮质增生症(CAH)是一种罕见的常染色体隐性疾病,由位于10q24.3染色体上的细胞色素P450家族17亚家族A成员1(CYP17A1)基因突变引起,导致17α-羟化酶/17,20-裂解酶缺乏。该疾病的特征是血液中雌激素、雄激素和皮质醇水平较低,这导致促肾上腺皮质激素水平代偿性增加,刺激盐皮质激素前体的产生。这随后导致高血压、低钾血症、原发性闭经和性幼稚症。在患有这种疾病的患者中已鉴定出90多种不同的基因损伤。CYP17A1基因常见突变的患病率在不同种族群体中有所不同。这种疾病的治疗包括补充糖皮质激素和性类固醇。对于生物学上为男性且被认定为女性的17α-羟化酶缺乏症患者,仅开具雌激素。然而,基因上为女性的患者可能会接受雌激素和孕激素补充治疗。在本研究中,对一名17岁的女性进行了检查,该女性患有17α-羟化酶/17,20-裂解酶缺乏症,表现为原发性闭经和性幼稚症,且无高血压。患者的核型为46,XX,基因分析显示外显子6和8存在复合杂合突变,导致17α-羟化酶/17,20-裂解酶活性完全缺失。该患者接受了泼尼松龙和炔雌醇治疗。此外,还介绍了有关CAH的近期文献综述。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/87b0/5355729/4407677e50de/MMR-15-01-0339-g00.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验